slides · global inventory
All filtered slides
Global slide inventory for the active corpus filters, with each row opening the slide detail view.
Corpus coverage
319,975 slides
319,974 are described (100%), so the treemap can explain the corpus instead of just counting files.
- Total slides
- 319,975
- Described
- 319,974
- Pending
- 1
100%ready for canon
Slide type composition
dynamicclickable
Slide type
Showing 319,974 described slides — 100.0% of 319,975 rendered pages
+Context & problem43,76713.7% · 6,592 docs+Data & charts72,62022.7% · 8,666 docs+Meta & navigation45,93614.4% · 9,739 docs+Recommend & act67,04121.0% · 9,324 docs+Cases & evidence31,2569.8% · 6,067 docs+Frameworks2,1230.7% · 1,232 docs+Appendix35,68211.2% · 6,614 docs+Other21,5496.7% · 5,566 docs
Tile area is proportional to slide count. Click a category to open its subtype map.
all document kinds · all orientations
Slide collection
230,701-230,730 of 319,975
40
The slide uses a four-column layout with upward-pointing arrows to signify growth/improvement.Hugo Boss | Results Presentation Deck | 44 slides · Hugo Boss
Conference presentation Investor relations Beat · Action1 hit
41
The slide uses a split-screen layout with key drivers on the left and a bar chart on the right.Hugo Boss | Results Presentation Deck | 44 slides · Hugo Boss
Conference presentation Investor relations Beat · Action1 hit
42
This is a transition or summary slide, likely setting the stage for the operational and financial sections of the presentation.Hugo Boss | Results Presentation Deck | 44 slides · Hugo Boss
Conference presentation Investor relations Beat · Action1 hit
43
Hugo Boss | Results Presentation Deck | 44 slidesHugo Boss | Results Presentation Deck | 44 slides · Hugo Boss
Conference presentation Investor relations Beat · Action1 hit
44
Hugo Boss | Results Presentation Deck | 44 slidesHugo Boss | Results Presentation Deck | 44 slides · Hugo Boss
Conference presentation Investor relations Beat · Action1 hit
01
Immix Biopharma | Investor Presentation Deck | 56 slidesImmix Biopharma | Investor Presentation Deck | 56 slides · Immix Biopharma
Pitch deck Investor relations 1 hit
02
Immix Biopharma | Investor Presentation Deck | 56 slidesImmix Biopharma | Investor Presentation Deck | 56 slides · Immix Biopharma
Pitch deck Investor relations 1 hit
03
The slide uses a three-column layout for strategic pillars followed by a bottom section highlighting clinical performance metrics.Immix Biopharma | Investor Presentation Deck | 56 slides · Immix Biopharma
Pitch deck Investor relations 1 hit
04
The slide uses a grid-based layout to categorize team members into three distinct organizational tiers.Immix Biopharma | Investor Presentation Deck | 56 slides · Immix Biopharma
Pitch deck Investor relations 1 hit
05
The slide uses a Gantt-style chart to represent clinical trial stages.Immix Biopharma | Investor Presentation Deck | 56 slides · Immix Biopharma
Pitch deck Investor relations 1 hit
06
The slide uses a visual arrow graphic to imply forward momentum.Immix Biopharma | Investor Presentation Deck | 56 slides · Immix Biopharma
Pitch deck Investor relations 1 hit
07
The slide uses a structural diagram to map technical modifications to clinical outcomes.Immix Biopharma | Investor Presentation Deck | 56 slides · Immix Biopharma
Pitch deck Investor relations Beat · Solution1 hit
08
The slide uses a comparison framework to contrast standard industry benchmarks with the company's clinical data.Immix Biopharma | Investor Presentation Deck | 56 slides · Immix Biopharma
Pitch deck Investor relations Beat · Solution1 hit
09
The slide uses a process flow diagram to connect cellular pathology to clinical organ damage.Immix Biopharma | Investor Presentation Deck | 56 slides · Immix Biopharma
Pitch deck Investor relations Beat · ProblemLoop · Cost Of Inaction1 hit
10
Includes a biological pathway diagram showing B-cell maturation and a pyramid diagram showing the hierarchy of disease targeting.Immix Biopharma | Investor Presentation Deck | 56 slides · Immix Biopharma
Pitch deck Investor relations Beat · SolutionLoop · Cost Of Inaction1 hit
11
Includes a biological process diagram showing the interaction between NXC-201 CAR-T cells and disease-causing LLPC clones.Immix Biopharma | Investor Presentation Deck | 56 slides · Immix Biopharma
Pitch deck Investor relations Beat · SolutionLoop · Cost Of Inaction1 hit
12
Includes dot plot for BCMA expression, bar chart for IFNy activation, and flow cytometry plots showing cell elimination.Immix Biopharma | Investor Presentation Deck | 56 slides · Immix Biopharma
Pitch deck Investor relations Beat · SolutionLoop · Cost Of Inaction1 hit
13
Uses a bar chart to compare CRS duration in days across four competitors, with NXC-201 highlighted as significantly lower.Immix Biopharma | Investor Presentation Deck | 56 slides · Immix Biopharma
Pitch deck Investor relations Beat · AgitateLoop · Cost Of Inaction1 hit
14
The slide uses a bar chart to compare neurotoxicity percentages and a table to compare clinical metrics like CRS onset and duration.Immix Biopharma | Investor Presentation Deck | 56 slides · Immix Biopharma
Pitch deck Investor relations Beat · AgitateLoop · Cost Of Inaction1 hit
15
The slide highlights NXC-201's 100% overall response rate and superior cardiac response compared to CAEL-101 and Birtamimab.Immix Biopharma | Investor Presentation Deck | 56 slides · Immix Biopharma
Pitch deck Investor relations Loop · Cost Of Inaction1 hit
16
The chart is a swimmer plot showing patient response duration, with an annotation indicating the target population for future enrollment.Immix Biopharma | Investor Presentation Deck | 56 slides · Immix Biopharma
Pitch deck Investor relations Loop · Quick Win Big Bet1 hit
17
The slide uses a visual comparison between existing standard-of-care treatments (left) and the NXC-201 opportunity (center/right).Immix Biopharma | Investor Presentation Deck | 56 slides · Immix Biopharma
Pitch deck Investor relations Beat · Market SizeLoop · Quick Win Big Bet1 hit
18
N-GENIUS TECHNOLOGY PLATFORM; NEXICART-1 Clinical Trial Data.Immix Biopharma | Investor Presentation Deck | 56 slides · Immix Biopharma
Pitch deck Investor relations Loop · Quick Win Big Bet1 hit
19
Includes comparative data points for transduction efficiency and experimental data for tonic signaling and exhaustion.Immix Biopharma | Investor Presentation Deck | 56 slides · Immix Biopharma
Pitch deck Investor relations Loop · Quick Win Big Bet1 hit
20
Includes citations from Nature Medicine and Signal Transduction and Targeted Therapy to validate the scientific approach.Immix Biopharma | Investor Presentation Deck | 56 slides · Immix Biopharma
Pitch deck Investor relations Loop · Quick Win Big Bet1 hit
21
Uses a combination of bar charts for preclinical data and a comparison table for clinical outcomes to demonstrate the superiority of the CD8 hinge optimization.Immix Biopharma | Investor Presentation Deck | 56 slides · Immix Biopharma
Pitch deck Investor relations Loop · Quick Win Big Bet1 hit
22
The slide uses a schematic to compare HSL and LSH configurations, showing superior performance for HSL in expansion and cytotoxicity metrics.Immix Biopharma | Investor Presentation Deck | 56 slides · Immix Biopharma
Pitch deck Investor relations Loop · Quick Win Big Bet1 hit
23
Includes a footnote citing FDA approval precedents for single-arm studies.Immix Biopharma | Investor Presentation Deck | 56 slides · Immix Biopharma
Pitch deck Investor relations Loop · Quick Win Big Bet1 hit
24
Immix Biopharma | Investor Presentation Deck | 56 slidesImmix Biopharma | Investor Presentation Deck | 56 slides · Immix Biopharma
Pitch deck Investor relations 1 hit
25
The slide uses a comparative diagram to show structural differences between NXC-201 and Abecma.Immix Biopharma | Investor Presentation Deck | 56 slides · Immix Biopharma
Pitch deck Investor relations 1 hit